BioSpace News Archive

Myriad Genetics, Inc., a leader in molecular diagnostics and personalized medicine, announced that Mark C. Capone, president and CEO, is scheduled to present at the J.P. Morgan 2020 Healthcare Conference at 3:00 p.m. PST on January 13, 2020 in San Francisco..

Arena Pharmaceuticals, Inc. will provide a corporate update highlighting its strategic portfolio expansion on a conference call tomorrow, January 7, at 9:00 AM ET, and provide additional detail at the 38th Annual J.P. Morgan Healthcare Conference taking place January 13-16, 2020.

NuVasive, Inc. announced that management will present at the 38th Annual J.P. Morgan Healthcare Conference at the Westin St. Francis in San Francisco on Wednesday, Jan. 15, at 10:00 a.m. PT/1:00 p.m. ET..

Jazz Pharmaceuticals plc announced that the company will be webcasting its corporate presentation at the 38th Annual J.P. Morgan Healthcare Conference in San Francisco, CA.

Silicon Therapeutics announced three additions to its management team to help lead the company through its next stage of growth. Humphrey Gardner, MD, FCAP has joined the company as Chief Medical Officer; Christopher Borella, PhD, has joined as Vice President, Head of Operations; and Huafeng Xu, PhD, has joined as Chief Technology Officer.

Universal Display Corporation announced its participation in the following investor and industry conferences.

The MEDICREA® Group announced that the United States Patent Office has recently issued the Company 7 additional key patents related to the UNiD™ ASI proprietary technology platform.

NextCure, Inc. announced that the company will present at the 38th Annual J.P. Morgan Healthcare Conference being held January 13-16, 2020, in San Francisco, California.

Radius Health, Inc., announced that its senior executive management team will present a corporate update at the 38th Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2020 at 11:30 am PST at the Westin St. Francis Hotel in San Francisco, California.

Results show a mini dose (150 µg) of RTU glucagon prevents Exercise-Induced Hypoglycemia (EIH) during prolonged, moderate-to-high intensity aerobic exercise in a clinical research setting